High-dose chemotherapy followed by autologous blood cell transplantation: A safe and effective outpatient approach

Bone Marrow Transplantation

Volumn 20, Issue 6, 1997, Pages 431-434

  Gluck S ^a   Des Rochers, C ^a   Cano, C ^a   Dorreen, M ^a   Germond, C ^a   Gill, K ^a   Lopez, P ^a   Sinoff, C ^a  

^a Northeastern Ontario Regional Cancer Centre   (Canada)

Author keywords

Breast cancer; High dose chemotherapy; Outpatient transplantation

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIMETHYL SULFOXIDE; MITOXANTRONE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST; VINBLASTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BLEEDING; BLOOD CELL; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; OUTPATIENT; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0742316670     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700901     Document Type: Article

References (26)

1. Canadian cancer statistics 1996. National Cancer Institute of Canada Statistics Canada; Provincial/Territorial Cancer Registries Health Canada.
2. Sledge GW, Antman KH. Progress in chemotherapy for metastatic breast cancer. Semin Oncol 1992; 19: 317-332.
3. Aisner J, Cirrincione C, Perloff M et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast -a randomized phase III trial comparing CAF vs VATH vs VATH alternating with CMFVP: Cancer and Leukaemia Group B Study 8281. J Clin Oncol 1995; 13: 1443-1452.
4. Fields KK, Elfenbein GJ, Lazarus HM et al. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 1995; 13: 323-332.
5. Peters WP, Ross M, Vredenburgh J et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1 143.
6. Shpall EJ, Jones JB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
7. Ghalie R, Williams SF, Valentino LA et al. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant 1995; 1: 40-46.
8. Williams SF, Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-1747.
9. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with haematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
10. Ho AD, Glück S, Germond C et al. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993; 7: 1738-1746.
11. Glück S, Porter K, Chadderton T et al. Depletion of DMSO (dimethylsulfoxide) prior to autografting after high-dose chemotherapy for metastatic breast cancer. Blood 1993; 82: 430a: 1705.
12. Glück S, Gagnon A. Neutropenic fever in patients after highdose chemotherapy followed by autologous haematopoietic progenitor cell transplantation and human recombinant granulocyte-macrophage colony stimulating factor. Bone Marrow Transplant 1994; 14: 989-990.
13. Glück S. Autologous transplantation for patients with advanced breast cancer with emphasis on bony metastasis. Canad J Oncol 1995; 5: 58-62.
14. Prins JM, Büller HJ, Kuijper EJ et al. Once vs thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-339.
15. Khaliq Y. Bence-Bruckler I. Bredeson C et al. Once daily ceftriaxone for febrile neutropenia in an outpatient blood and marrow transplant programme. Blood 1995; 86: 837.
16. Calandra T et al (The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer). Efficacy and toxicity of single daily doses of amikacin and ceftriaxone vs multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-593.
17. Gilbert C, Meisenberg B, Vredenburgh J et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994; 12: 1005-1011.
18. Alangaden G, Chandrasekar PH, Bailey E et al and the Bone Marrow Transplant Team. Antifungal prophylaxis with lowdose fluconazole during bone marrow transplantation. Bone Marrow Transplant 1994; 14: 919-924.
19. Gollard R, Meisenberg B, McMilland R. Miller W. Prophylactic antibiotics (PrABX) in peripheral blood progenitor cell (PBPC) transplants: virtual elimination of bacteraemia allows outpatient management. Blood 1995; 86: 839.
20. Glück S. Desrochers C, Gagnon A. Kaitila B. Safe and effective approach to an out-patient high-dose chemotherapy and peripheral blood progenitor/stem cell transplantation in patients with metastatic breast cancer, lnt J Oncol 1994; 5: 353-420.
21. Tepler I, Demetri G, McCauley M et al. Outpatient-based treatment with multiple cycles of dose-intensified ifosfamide, carboplatin and etoposide (ICE) chemotherapy supported by peripheral blood progenitor cells (PBPC) mobilized by G-CSF: efficient collection of progenitor cells with rapid haematologic recovery. Blood 1994; 84: 830.
22. Jagannath S, Vesole D, Tricot G, Barlogie B. 118 outpatient (OPT) autotransplants in multiple myeloma (MM). Blood 1994; 84: 832.
23. Meisenberg B, Miller W, McMilland R, Piro L. Near total outpatient transplants (NTOT): accumulated experience in 125 transplants with a financial analysis on a subset of patients (PTS). Blood 1995; 86: 840.
24. Miyahara TT, Dix SP, Devine SM et al. Evaluation of supportive care guidelines for monitoring breast cancer bone marrow transplant (BMT) patients in the outpatient setting. Blood 1995; 86: 838.
25. Rubenstein EB, Rolston KVI. Comments and critique. Outpatient treatment of febrile neutropenic patients with cancer. Eur J Can 1995; 31A: 2-4.
26. Kennedy MJ. High-dose chemotherapy of breast cancer: is the question answered? J Clin Oncol 1995; 13: 2477-2479.